Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. - Wikidata - awgldk - TriplyDB

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

http://www.wikidata.org/entity/Q43590541

about

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy The NF-κB Pathway and Cancer Stem Cells Drugging topoisomerases: lessons and challenges Boron chemicals in diagnosis and therapeutics Current and emerging strategies for the prevention of graft-versus-host disease Modulation of apoptosis sensitivity through the interplay with autophagic and proteasomal degradation pathways Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2 Irinotecan pharmacogenomics Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiation Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.Proteasome inhibitors in glioblastoma Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.Screening of potential molecular targets for colorectal cancer therapy.Nuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos The role of B cells in solid organ transplantation.The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.p21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis.The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland.NF-κB, an active player in human cancers.Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib.A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.Nuclear factor κ-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy.IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent Regulation of ΔNp63α by NFκΒ Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.Nf-kappa B, chemokine gene transcription and tumour growth Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells.The role of proteasome inhibition in nonsmall cell lung cancer Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers.

P2860

Q24814325-ECBBF0C9-95C9-4400-8E02-1FC1C61FAE29 Q26750605-B0F8F5EA-3A5C-420D-A26D-2D87F7860E4D Q27000099-BD407F58-F35E-4515-AF8A-C844C47EEE31 Q27006075-1D8541FA-2DFA-4E42-9DED-F24E2996BAD9 Q27016541-939F5D61-E6D8-42CB-811D-776381317ED3 Q27016574-626D81FE-3998-4BF0-92D3-2F8340D41A30 Q28209990-6E2E3341-A809-4296-9036-3C37E6E7C68B Q28287024-003C52A9-E5BC-41CF-8842-CD244C6E5B01 Q28476078-5E85A5FE-225C-45A5-88A8-222BF0145B7E Q28534151-7BDDE88B-5470-4505-9AB6-4656357EA304 Q28763731-90325FBE-E3EB-4C4E-AC0F-99C00E4A1104 Q33382930-79E1EE17-C2F8-49D4-9F16-500A0EBE5C1A Q33391857-C934A5AD-E0DD-43EC-8EC0-C396BA4A77C3 Q33396761-D15F238B-2093-4E3F-AF05-2BDA032CA77E Q33598931-1E48BD10-981F-43D4-B0B4-1B9EA9764620 Q33656653-8211421A-8B66-48E7-8699-76D9CF9EBCD1 Q33717413-9100B93E-3731-4542-9064-0E293FB47712 Q33735051-2C29DF91-2E4F-4B21-8481-FB1FAC269860 Q33757740-2DFBB1C4-0B8F-494E-84ED-E02CC54A9A33 Q33891696-5CFCF8BF-7AA6-4DD3-ADF0-24D298D4EBD2 Q33916030-AC34E7D3-D247-4EAB-8861-61494E09C50D Q33921377-C9E2130B-41DD-4A8D-A78F-818C59BCA156 Q33943227-73A80BF1-4787-4967-85BF-D43789ECF799 Q34000612-7B8028AE-FBCF-4F57-A2F4-FEFE356D1363 Q34008793-B85BEE13-DA4F-4966-B5F0-BB9914114D97 Q34124144-822760F3-2ABD-4487-AEB6-DF3A1E365205 Q34138728-FE075DF0-BA62-474E-B187-9C7643747427 Q34205125-7CE98E43-69F2-4FBD-B943-81CE99ADBD7B Q34225158-12611C63-7A12-4B98-B342-123058D3BDE2 Q34294361-B656D485-80D9-43BF-AC84-1286F4DECBF3 Q34307050-AFE1C88F-5F67-4F51-94CC-6F42D2AFF0AF Q34442153-BA4CA5C3-CEB7-4A3D-8C34-4EC09D85F51B Q34598755-4385E15B-8DAE-4484-83A0-734726B88D71 Q34610605-D6256464-3C37-40F2-A488-B179022AC2D3 Q34619787-6898BC75-C150-4A10-89DF-5FF884B32487 Q34662185-A154033E-C56F-4222-9E8C-80C4895141AF Q34810265-A71C80CC-2070-4A24-802D-56F0434235D5 Q34946954-170AEFDF-932E-4126-A343-41573F21A326 Q35001441-1E776EE5-E1D1-4A46-A057-A0E9298B62C4 Q35127221-126A86E9-D833-4DEF-8962-35B451362BD6

P2860

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

http://www.wikidata.org/entity/Q43590541

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Enhanced chemosensitivity to C ...... lear factor-kappaB inhibition.

@en

Enhanced chemosensitivity to C ...... lear factor-kappaB inhibition.

@nl

type

label

Enhanced chemosensitivity to C ...... lear factor-kappaB inhibition.

@en

Enhanced chemosensitivity to C ...... lear factor-kappaB inhibition.

@nl

prefLabel

Enhanced chemosensitivity to C ...... lear factor-kappaB inhibition.

@en

Enhanced chemosensitivity to C ...... lear factor-kappaB inhibition.

@nl

P1433

Q43590541-10602223-957E-428F-95F1-1CCCDD6EF504

P1476

Q43590541-5FC63926-6A22-4CF2-AB19-99003C769E50

P2093

Q43590541-298D7EBA-57E7-4D89-A36A-BA4B96C888BD

Q43590541-51425E20-4A1D-45F2-B5A9-A501AC3DDA83

Q43590541-5B6F5872-14D7-4F03-8C60-8AFBFE84A2E0

Q43590541-6AE0B22B-6E17-4DBC-9354-2AD528F178A9

Q43590541-6E22CE3D-5773-4B3A-A3D0-C479885AEF0B

Q43590541-BBEF64F3-0323-4E00-93BB-C82AA6EF4A63

Q43590541-D473A8EA-3D3B-40A0-B522-3EAF5F874D44

P304

Q43590541-F170A95F-0B28-4C67-BB02-F0BD3D0DBE70

P31

Q43590541-E0843C3E-6721-4AFA-A832-66A180EB4154

P407

Q43590541-777F4698-0782-46F8-93ED-1EEC286C8625

P433

Q43590541-CC0C6A6A-8960-43CF-83F4-2228984CACF7

P478

Q43590541-FFAAD281-C67D-4AA4-B2B8-1E449130B99A

P577

Q43590541-F39E3C00-20BB-4385-8722-87F26E6BD0AC

P698

Q43590541-A1A9F517-38E0-4D23-9487-C3B1647C68CB

P1433

Cancer Research

P1476

Enhanced chemosensitivity to C ...... clear factor-kappaB inhibition

@en

P2093

A S Baldwin

http://www.w3.org/2001/XMLSchema#string

J Adams

http://www.w3.org/2001/XMLSchema#string

J C Cusack

http://www.w3.org/2001/XMLSchema#string

K Abendroth

http://www.w3.org/2001/XMLSchema#string

M Houston

http://www.w3.org/2001/XMLSchema#string

P J Elliott

http://www.w3.org/2001/XMLSchema#string

R Liu

http://www.w3.org/2001/XMLSchema#string

P304

3535-3540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2001-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11325813

http://www.w3.org/2001/XMLSchema#string